
Korro Reports Full Year 2024 Financial Results and Provides Business Updates
— Completed dosing of first two cohorts in Phase 1/2a REWRITE Clinical Study of KRRO-110 for Alpha-1 Antitrypsin Deficiency (AATD); Interim readout expected in the second half of 2025 — U.S. Food and Drug Administration (FDA) Granted Orphan Drug …